Dezawa MuseCells® are unique repair cells found naturally in the body. Other stem cell types, such as embryonic stem cells and iPSCs, carry a risk of tumor formation, while traditional MSCs can show mixed results in potency and immune response. Dezawa MuseCells® have shown a safer profile in comparison—showing no evidence of tumor formation*, working across more tissue types, and being used in clinical settings without the need for immunosuppressants, even in patients as young as newborns and as old as the elderly.
Dezawa MuseCells® carry a naturally immune-privileged profile—allowing for allogenic
(donor-based) administration without triggering rejection or requiring
immunosuppressive drugs.
With no serious immune-related adverse events reported to date, Dezawa MuseCells® have been
delivered without immunosuppression in:
(SHIELD trial–HIE)
(Stroke & MI trials)
(ALS–Phase 2a)
Dezawa MuseCells® are naturally pluripotent—not reprogrammed or genetically modified.
In both preclinical and clinical settings, Dezawa MuseCells® have not shown evidence of tumor formation, even under conditions where other stem cell types may form tumors.* They have consistently demonstrated controlled differentiation and stable behavior, including under stress.
Unlike embryonic stem cells or iPSCs, Dezawa MuseCells® have not exhibited the unregulated or undifferentiated growth patterns linked with tumorigenic risk in published studies to date.
Disclaimer:
All referenced findings are based on Dezawa MuseCells® manufactured in accordance with MCI’s patented processes. Published findings cannot be assumed to apply to cells produced outside of these methods.
DEZAWA MUSE CELLS® HAVE NEVER FORMED TERATOMAS IN ANY STUDY, MODEL, OR PATIENT POPULATION TO DATE.*
Disclaimer: Evidence to date applies exclusively to Dezawa MuseCells® created under MCI’s patented methods. Variations in manufacturing are not covered by these findings.
Dezawa MuseCells® are shaping new benchmarks for regulated regenerative medicine and improved safety.
